Last Updated:
Searching
Create account to add to watchlist!

Frazier Lifesciences Acquisition Corp - FLAC

  • Commons

    $9.79

    +0.00%

    FLAC Vol: 2.5K

  • Warrants

    $0.77

    -1.28%

    FLACW Vol: 2.4K

  • Units

    $10.03

    +0.10%

    FLACU Vol: 1.4K

Average: 0
Rating Count: 0
You Rated: Not rated

Please log in to rate.

SPAC Stats

Market Cap: 139.6M
Average Volume: 24.6K
52W Range: $9.56 - $12.39
Weekly %: -0.31%
Monthly %: -0.10%
Inst Owners: 43

Info

Target: Searching
Days Since IPO: 355
Unit composition:
Each unit has an offering price of  $10.00 and consists of one Class A ordinary share and one-third of one redeemable warrant
Trust Size: 10000000.0M

Management

Our officers and directors are as follows: Name ​ ​ Age ​ ​ Position ​ James N. Topper, M.D., Ph.D. ​ ​ ​ ​ 58 ​ ​ ​ Chief Executive Officer and Chairman ​ David Topper ​ ​ ​ ​ 63 ​ ​ ​ Chief Financial Officer and Director ​ Gordon Empey ​ ​ ​ ​ 52 ​ ​ ​ Vice President and General Counsel ​ Max M. Nowicki, M.D. ​ ​ ​ ​ 31 ​ ​ ​ Vice President, Acquisitions ​ Robert F. Baltera ​ ​ ​ ​ 55 ​ ​ ​ Director ​ Michael F. Bigham ​ ​ ​ ​ 63 ​ ​ ​ Director ​ Carol G. Gallagher, Pharm.D. ​ ​ ​ ​ 56 ​ ​ ​ Director ​ Krishna R. Polu, M.D. ​ ​ ​ ​ 47 ​ ​ ​ Director ​ James N. Topper, M.D., Ph.D., serves as our Chief Executive Officer and Chairman of our board of directors. Mr. Topper currently serves as a Managing Partner of Frazier Life Sciences. He joined Frazier in 2003 and opened Frazier’s Menlo Park office in the same year. Throughout his 15 years as a Managing Partner, Mr. Topper has invested across over 35 companies encompassing a broad spectrum of life science and biopharmaceutical companies. Mr. Topper has led and served as a board member for many of Frazier’s successful life sciences investments, including Acerta Pharma BV (sold to AstraZeneca), Calistoga Pharmaceuticals (co-founder, sold to Gilead Sciences), Mavupharma (sold to AbbVie), Rempex (sold to The Medicines Company), Incline (co-founder, sold to The Medicines Company), Alnara (sold to Lilly), Portola (co-founder, NASDAQ: PTLA), CoTherix (sold to Actelion), and Threshold (NASDAQ: THLD). He currently represents Frazier on the boards of Allena Pharmaceuticals (NASDAQ: ALNA), Alpine Immune Sciences (NASDAQ: ALPN), Amunix Pharmaceuticals, AnaptysBio (NASDAQ: ANAB), Lassen Therapeutics, and Phathom Pharmaceuticals (NASDAQ: PHAT). In 2011 and 2016, Mr. Topper was named to the Midas List of leading venture capitalists, and in 2013, Mr. Topper was recognized by Forbes as a top ten healthcare investor. Prior to joining Frazier, Mr. Topper was the head of cardiovascular R&D at Millennium Pharmaceuticals and ran Millennium San Francisco (formerly COR Therapeutics). Before the merger of COR and Millennium, he served as the Vice President of Biology at COR and was responsible for all research activities. He served on the medical school faculties at Stanford and Harvard Medical School prior to joining COR. Mr. Topper received his M.D. and Ph.D. in Biophysics from Stanford and his B.S. from the University of Michigan. He completed his postgraduate training in Internal Medicine and Cardiovascular Disease at the Brigham and Women’s Hospital in Boston. He has authored over 50 publications and was the recipient of a Howard Hughes Scholars Award while on the faculty at Stanford. He is also a board observer for Alcresta Therapeutics and Sojournix. We believe that Mr. Topper’s broad operational and transactional experience across numerous life sciences and biopharmaceutical companies makes him well qualified to serve as our Chairman and Chairman of the board of directors. David Topper serves as our Chief Financial Officer and on our board of directors. Mr. Topper has served as Senior Advisor for Capital Markets at Frazier since March 2020. Since February 2020, Mr. Topper has also served as Senior Managing Director at CircleUp, where he is also an investor and board observer. Mr. Topper currently serves as a member of the board of directors of Amherst Pierpont Securities and previously served as a member of the board of directors of Engility Corp., TASC, Affinion Group and MeteoGroup. From 2012 to 2019, Mr. Topper was an Operating Partner at General Atlantic, providing capital markets expertise to portfolio companies. Prior to General Atlantic, Mr. Topper was Co-Head of Equity Capital Markets at J.P. Morgan, where he led many of the firm’s major advisory and capital-raising transactions and worked with the U.S. Treasury and other regulatory agencies on crisis-related issues. He also served as Chairman of the Commitments Committee at J.P. Morgan. Prior to J.P. Morgan, Mr. Topper spent 22 years at Morgan Stanley, where he served as Co-Head of U.S. Equity Capital Markets, Managing 111 TABLE OF CONTENTS Director, and Chairman of the Equity Commitment Committee. Earlier in his career, he held several other senior management positions in Morgan Stanley’s Debt Capital Markets, Leveraged Finance, and Mergers & Acquisitions departments. David received his B.A. from Duke University and his M.B.A. from Stanford Graduate School of Business. We believe that Mr. Topper’s broad operational and transactional experience makes him well qualified to serve as our Chief Financial Officer and as a member of our board of directors. Gordon Empey serves as our Vice President and General Counsel. Mr. Empey joined the Frazier Life Sciences team in 2017, where he currently serves as a Partner and General Counsel. He has over 20 years of experience as counsel to venture capital investors and life sciences companies. Prior to joining Frazier Life Sciences, Mr. Empey was a partner with Cooley LLP, one of the premier biotechnology and technology law firms, until June 2017. In his legal practice at Cooley, Mr. Empey focused on emerging growth companies, corporate securities and mergers & acquisitions, and worked closely with Frazier Life Sciences on several investments and company creation efforts. Mr. Empey also advised numerous other life sciences venture capital firms and companies on structuring investments and corporate matters. Before joining Cooley, Mr. Empey was Executive Vice President and General Counsel at Radiant Research from May 2004 to August 2007, when it was sold to Covance and Swiss Biosciences. Earlier in his career, Mr. Empey served as an officer in the United States Navy, Judge Advocate General Corps. Mr. Empey received his J.D. from the University of California at Berkeley, Boalt Hall, and his B.A. from Colgate University. Max M. Nowicki, M.D., serves as our Vice President, Acquisitions. Mr. Nowicki joined Frazier as an associate in 2019, with a focus on identifying and evaluating new investment opportunities in the life sciences sector. Prior to joining Frazier, Mr. Nowicki founded and managed King Tide Capital Management, an investment fund focused on public biotech investments, from February 2018 to July 2019. Prior to King Tide Capital, Mr. Nowicki was a senior business analyst at Zymergen, a synthetic biology company, from March 2017 to February 2018. Prior to that, Mr. Nowicki was an investment banking analyst in the healthcare mergers & acquisitions group at Evercore Partners, focusing on biotech and medtech companies. Mr. Nowicki received his M.D. from the Weill Cornell Medical College of Cornell University, where he was awarded the Siegel Family Student Prize, and his B.A. in physics and biochemistry from Bowdoin College. Robert F. Baltera serves on our board of directors. Mr. Baltera has served as President and Chief Executive Officer and on the board of directors of Cirius Pharmaceuticals since March 2017. Mr. Baltera joined Frazier as an Entrepreneur in Residence in January 2016, where he co-founded Hawkeye Therapeutics, Inc., a search company focused on in-licensing and developing high-quality assets from pharmaceutical companies. Mr. Baltera has also served as the Executive Chairman of Mavupharma, Inc. since March 2017. From February 2015 until December 2015, Mr. Baltera served as Chief Executive Officer and a member of the board of directors of Laguna Pharmaceuticals, Inc., a biotechnology company. Mr. Baltera was the Chief Executive Officer of Amira Pharmaceuticals, Inc., a pharmaceutical development company, a position he held from July 2007 through September 2011, when Amira was sold to Bristol-Myers Squibb. Prior to Amira, Mr. Baltera held a number of senior management positions at Amgen (NASDAQ: AMGN) over 17 years, most recently serving as Vice President of Corporate and Contract Manufacturing. Mr. Baltera served on the board of directors of Organovo Holdings, Inc. (NASDAQ: ONVO) from October 2009 to August 2019, and served as Lead Independent Director from June 2014 through August 2016. Mr. Baltera previously served on the board of directors of Xencor, Inc. (NASDAQ: XNCR), a biotechnology development company. He currently serves on the board of directors of Imago BioSciences, Inc., Panmira Pharmaceuticals, LLC and the San Diego Venture Group. He is also a Business Advisory Panel member of PBS Biotech Inc.. Mr. Baltera received his M.B.A. from the Anderson School at the University of California, Los Angeles, and an M.S. in genetics and a B.S. in microbiology from The Pennsylvania State University. Mr. Baltera attended the Director Education and Certification program at the University of California, Los Angeles. We believe that Mr. Baltera’s experience in managing biotechnology and pharmaceutical companies, as well as his experience as a public company director, make him well qualified to serve as a member of our board of directors. Michael F. Bigham serves on our board of directors. Mr. Bigham has served as the Executive Chairman of the board of directors of Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) since June 2019. Prior to that, he was Chief Executive Officer and Chairman of the board of directors of Paratek from October 2014. 112 TABLE OF CONTENTS Mr. Bigham has more than 25 years of senior leadership experience in the biopharmaceutical industry. From January 2003 to November 2015, he was a General Partner at Abingworth LLP, a leading international investment group dedicated to life sciences and healthcare. From November 2015 to December 2018, he served as part-time Executive Partner at the firm. He currently serves as a member of the board of directors of Adamas Pharmaceuticals (NASDAQ: ADMS). He has previously served on the board of directors of Inmediata, where he was also Chairman, and Avila Therapeutics, where he was also the founding Chairman and Chief Executive Officer. He has also previously served on the board of directors of Magellan Biosciences, Portola Pharmaceuticals, Supernus Pharmaceuticals (NASDAQ: SUPN), Avedro and Valeritas. He was formerly Vice Chairman of Corixa Corporation, a then-public biotechnology company, and was President and Chief Executive of Coulter Pharmaceuticals, a then-public oncology company, until it merged into Corixa. Previously, he was an early employee at Gilead Sciences (NASDAQ: GILD), where he served in various capacities, including Executive Vice President of Operations and Chief Financial Officer. Before joining Gilead Sciences, he was a Partner at Hambrecht & Quist, where he became Co-Head of Healthcare Investment Banking. Mr. Bigham received his B.S. from the University of Virginia and qualified as a C.P.A. before completing his M.B.A. at Stanford University. We believe that Mr. Bigham’s broad operational and transactional experience, as well as his experience as a public company director, make him well qualified to serve as a member of our board of directors. Carol G. Gallagher, Pharm.D., serves on our board of directors. Dr. Gallagher has served as a Venture Partner at New Enterprise Associates since 2014. Dr. Gallagher has over nine years of experience as a director in public and private companies and over 30 years of experience in biopharmaceutical companies. Dr. Gallagher is currently a director of Atara Biotherapeutics (NASDAQ: ATRA), where she has served since January 2013, and Chairman of the board of directors of Millendo Therapeutics (NASDAQ: MLND), where she has served since February 2013. She also serves as a director at Metacrine (NASDAQ: MTCR), PIONYR Immunotherapeutics, Annexon (NASDAQ: ANNX), Qpex BioPharma, Recludix, TRex Bio, Turning Point Therapeutics (NASDAQ: TPTX) and Chromacode. She previously served as a director at Aragon Pharmaceuticals, Seragon Pharmaceuticals, AnaptysBio (NASDAQ: ANAB) and eFFECTOR Therapeutics. From 2008 to 2011, Dr. Gallagher was the President and Chief Executive Officer of Calistoga Pharmaceuticals, which developed the first-in-class cancer therapeutic, CAL-101, and was acquired by Gilead Sciences in 2011. CAL-101 was approved as ZYDELIG in the US and Europe in 2014. Earlier in her career, she held commercial and drug development roles within Eli Lilly (NYSE: LLY), Amgen (NASDAQ: AMGN), Agouron, Pfizer (NYSE: PFE) and Biogen (NASDAQ: BIIB). She studied chemistry at Vanderbilt University and then attained her B.S. and Doctor of Pharmacy degrees from the College of Pharmacy at the University of Kentucky. We believe that Dr. Gallagher’s experience in managing biotechnology and pharmaceutical companies, as well as her experience as a public company director, make her well qualified to serve as a member of our board of directors. Krishna R. Polu, M.D., serves on our board of directors. Mr. Polu has served as the Executive Vice President R&D of Equillium, Inc. (NASDAQ: EQ) since August 2018, and Chief Medical Officer since January 2020. Mr. Polu also serves as a member of the board of directors of Goldilocks Therapeutics, where he previously served as a strategic advisor from February 2018 to January 2020. Prior to that, Mr. Polu was an Entrepreneur in Residence at Frazier from February 2017 to August 2018, where he founded Expedition Therapeutics, a search company focused on identifying and in-licensing assets in the kidney and autoimmune therapeutic areas. During this time, he also served as interim Chief Executive Officer of Scout Bio, a company focused on the discovery and development of gene therapies for companion animals. From January 2015 to December 2016, Mr. Polu served as Chief Medical Officer at Raptor Pharmaceuticals, a then-public company focused on rare diseases, until its acquisition by Horizon Pharmaceuticals for $800 million. In that role, he oversaw clinical development, regulatory affairs, pharmacovigilance and medical affairs, and was responsible for securing additional drug approvals for Procysbi in nephropathic cystinosis, supporting product launches for Quinsair in cystic fibrosis, and advancing the pipeline in other rare diseases including Huntington’s disease, cystic fibrosis, bronchiectasis and nontuberculous mycobacteria. Prior to Raptor, Mr. Polu served as Chief Medical Officer at CytomX Therapeutics (NASDAQ: CTMX) and directed preclinical development and translational research efforts for the Probody platform in oncology and helped secure a number of Pharma partnerships. Prior to CytomX, he led clinical development and 113 TABLE OF CONTENTS pharmacovigilance activities at Affymax, a then-public biopharmaceutical company, where he was instrumental in securing FDA approval of peginesatide for the treatment of anemia in patients on dialysis. Mr. Polu also held senior level positions in clinical development at Amgen (NASDAQ: AMGN) and was responsible for leading clinical development programs in heart failure, anemia of chronic kidney disease, and diabetes. Mr. Polu currently serves as an advisor to Trestle Biotherapeutics, Medikine, and Mineralys Therapeutics. Mr. Polu is also the co-founder of Lassen Therapeutics, where he also serves as an advisor. Mr. Polu received his B.A. in Human Biology from Stanford University and his M.D. from the University of Texas Health Science Center, San Antonio. He completed his residency in internal medicine at the University of Colorado followed by a clinical and research fellowship in nephrology at Harvard Medical School at the Brigham and Women’s Hospital and Massachusetts General Hospital. Mr. Polu has co-authored several scientific and clinical publications in the areas of genetics and renal disease. We believe that Mr. Polu’s broad biopharmaceutical and leadership experience makes him well qualified to serve as a member of our board of directors. We believe our board of directors and management team are well positioned to take advantage of the growing set of investment opportunities focused on the biotechnology sector, and that our contacts, relationships and investment and operating experience will allow us to generate an attractive transaction for our shareholders. There are no family relationships between any director, executive officer, or person nominated or chosen to become a director or officer, except that James N. Topper and David Topper are siblings. Number and Terms of Office of Officers and Directors Our board of directors is divided into three classes, with only one class of directors being appointed in each year, and with each class (except for those directors appointed prior to our first annual general meeting) serving a three-year term. The term of office of the first class of directors, consisting of Robert F. Baltera and Michael F. Bigham, will expire at our first general annual meeting. The term of office of the second class of directors, consisting of Carol G. Gallagher and Krishna R. Polu, will expire at our second annual general meeting. The term of office of the third class of directors, consisting of David Topper and James N. Topper, will expire at our third annual general meeting. Prior to the completion of an initial business combination, any vacancy on the board of directors may be filled by a nominee chosen by holders of a majority of our founder shares. In addition, prior to the completion of an initial business combination, holders of a majority of our founder shares may remove a member of the board of directors for any reason. Pursuant to an agreement to be entered into on or prior to the closing of this offering, our sponsor, upon and following consummation of an initial business combination, will be entitled to nominate three individuals for appointment to our board of directors, as long as the sponsor holds any securities covered by the registration and shareholder rights agreement. Our officers are appointed by the board of directors and serve at the discretion of the board of directors, rather than for specific terms of office. Our board of directors is authorized to appoint persons to the offices set forth in our amended and restated memorandum and articles of association as it deems appropriate. Our amended and restated memorandum and articles of association provides that our officers may consist of one or more chairman of the board, chief executive officer, chief financial officer, chief business officer, president, vice presidents, secretary, treasurer and such other offices as may be determined by the board of directors. Director Independence Nasdaq listing standards require that a majority of our board of directors be independent. An “independent director” is defined generally as a person other than an officer or employee of the company or its subsidiaries or any other individual having a relationship with the company which in the opinion of the company’s board of directors, could interfere with the director’s exercise of independent judgment in carrying out the responsibilities of a director. Upon the effectiveness of the registration statement of which 114 TABLE OF CONTENTS this prospectus forms a part, we expect to have “independent directors” as defined in Nasdaq’s listing standards and applicable SEC rules. Our board of directors has determined that each of Robert F. Baltera, Michael F. Bigham, Carol G. Gallagher and Krishna R. Polu are “independent directors” as defined in Nasdaq’s listing standards and applicable SEC rules. Our independent directors will have regularly scheduled meetings at which only independent directors are present. Executive Officer and Director Compensation None of our executive officers or directors have received any cash compensation for services rendered to us. Commencing on the date that our securities are first listed on Nasdaq through the earlier of

Holder Stats

1 0
% of Shares Held by All Insider 0.00%
% of Shares Held by Institutions 45.72%
% of Float Held by Institutions 45.72%
Number of Institutions Holding Shares 43

Mutual Fund Holders

Holder Shares Date Reported Value % Out
Investment Managers Ser Tr-Vivaldi Merger Arbitrage Fd 47500 2021-03-30 473100 0.72
Fidelity NASDAQ Composite Index Fund 5931 2021-03-30 59072 0.09

Institutional Holders

Reporting Date Hedge Fund Shares Held Market Value % of Portfolio Quarterly Change in Shares Ownership in Company
2021-11-22 EcoR1 Capital LLC 587,615 $5,770,000 0.2% +193.1% 3.310%
2021-11-16 Schonfeld Strategic Advisors LLC 29,031 $280,000 0.0% +49.8% 0.164%
2021-11-16 CNH Partners LLC 22,892 $220,000 0.0% -8.4% 0.129%
2021-11-15 Polar Asset Management Partners Inc. 190,897 $1,880,000 0.0% -4.6% 1.075%
2021-11-15 Glazer Capital LLC 5,128 $50,000 0.0% 0 0.029%
2021-11-15 Linden Advisors LP 178,701 $1,750,000 0.0% -1.9% 1.007%
2021-11-15 Dark Forest Capital Management LP 17,962 $180,000 0.1% 0 0.101%
2021-11-12 Ghisallo Capital Management LLC 319,658 $3,130,000 0.1% -1.1% 1.801%
2021-11-12 Magnetar Financial LLC 32,638 $320,000 0.0% +45.5% 0.184%
2021-11-08 Toronto Dominion Bank 63,483 $620,000 0.0% +3.3% 0.358%
2021-10-25 Exos Asset Management LLC 61,481 $600,000 0.3% +4.1% 0.346%
2021-08-17 Citadel Advisors LLC 554,251 $5,410,000 0.0% +0.8% 5.540%
2021-08-16 Alyeska Investment Group L.P. 753,492 $7,350,000 0.1% +5.4% 7.531%
2021-08-16 Vivaldi Asset Management LLC 89,444 $870,000 0.1% +88.3% 0.894%
2021-08-16 Schonfeld Strategic Advisors LLC 19,381 $190,000 0.0% +85.9% 0.194%
2021-08-16 Echo Street Capital Management LLC 309,160 $3,020,000 0.0% +131.9% 3.090%
2021-08-16 Linden Advisors LP 182,181 $1,780,000 0.0% -3.4% 1.821%
2021-08-13 Laurion Capital Management LP 50,000 $490,000 0.0% 0 0.500%
2021-08-13 MYDA Advisors LLC 410,299 $4,010,000 1.0% 0 4.101%
2021-08-13 Toronto Dominion Bank 61,433 $600,000 0.0% +77.9% 0.614%
2021-08-12 CIBC World Markets Inc. 51,500 $500,000 0.0% 0 0.515%
2021-08-11 Picton Mahoney Asset Management 99,996 $980,000 0.0% 0 0.999%
2021-08-10 Toronto Dominion Bank 61,433 $600,000 0.0% +77.9% 0.614%
2021-08-06 Magnetar Financial LLC 22,434 $220,000 0.0% 0 0.224%
2021-05-18 Castle Creek Arbitrage LLC 154,560 $1,530,000 0.1% 0 3.243%
2021-05-18 TENOR CAPITAL MANAGEMENT Co. L.P. 25,000 $250,000 0.0% 0 0.525%
2021-05-18 Fir Tree Capital Management LP 200,000 $1,990,000 0.1% 0 4.196%
2021-05-18 Berkley W R Corp 14,907 $150,000 0.0% 0 0.313%
2021-05-18 Alyeska Investment Group L.P. 715,002 $7,120,000 0.1% 0 15.002%
2021-05-18 Citadel Advisors LLC 550,000 $5,470,000 0.0% 0 11.540%
2021-05-18 Radcliffe Capital Management L.P. 250,000 $2,490,000 0.1% 0 5.245%
2021-05-17 Vivaldi Asset Management LLC 47,500 $470,000 0.1% 0 0.997%
2021-05-17 Schonfeld Strategic Advisors LLC 10,425 $100,000 0.0% 0 0.219%
2021-05-17 Vivaldi Capital Management LLC 12,500 $130,000 0.0% 0 0.262%
2021-05-17 CNH Partners LLC 25,000 $250,000 0.0% 0 0.525%
2021-05-17 Polar Asset Management Partners Inc. 199,998 $1,990,000 0.0% 0 4.196%
2021-05-17 Suvretta Capital Management LLC 87,498 $870,000 0.0% 0 1.836%
2021-05-17 Governors Lane LP 350,000 $3,490,000 0.2% 0 7.344%
2021-05-17 Sphera Funds Management LTD. 126,687 $1,260,000 0.1% 0 2.658%
2021-05-17 Centiva Capital LP 25,000 $250,000 0.0% 0 0.525%
2021-05-14 Periscope Capital Inc. 143,700 $1,430,000 0.1% 0 3.015%
2021-05-14 PEAK6 Investments LLC 139,899 $1,390,000 0.0% 0 2.935%
2021-05-13 Wolverine Asset Management LLC 8,467 $84,000 0.0% 0 0.178%
2021-05-13 DG Capital Management LLC 440,000 $4,380,000 1.0% 0 9.232%
2021-05-13 Atalaya Capital Management LP 10,000 $100,000 0.0% 0 0.210%
2021-05-11 Toronto Dominion Bank 34,528 $340,000 0.0% 0 0.724%
2021-05-05 Exos Asset Management LLC 47,825 $480,000 0.4% 0 1.003%
2021-05-04 Cowen AND Company LLC 24,397 $240,000 0.0% 0 0.512%

SEC Filings

Form Type Form Description Filing Date Document Link
10-Q 10-Q 2021-11-09 https://www.sec.gov/Archives/edgar/data/1828326/000119312521324421/d232750d10q.htm
10-Q 10-Q 2021-08-09 https://www.sec.gov/Archives/edgar/data/1828326/000119312521240492/d173852d10q.htm
SC 13G SCHEDULE 13G 2021-06-03 https://www.sec.gov/Archives/edgar/data/1828326/000110465921076356/tm2118430d2_sc13g.htm
10-Q 10-Q 2021-05-24 https://www.sec.gov/Archives/edgar/data/1828326/000119312521171117/d134566d10q.htm
10-K/A 10-K/A 2021-05-24 https://www.sec.gov/Archives/edgar/data/1828326/000119312521170830/d13011d10ka.htm
8-K 8-K 2021-05-24 https://www.sec.gov/Archives/edgar/data/1828326/000119312521170817/d898879d8k.htm
NT 10-Q NT 10-Q 2021-05-17 https://www.sec.gov/Archives/edgar/data/1828326/000119312521163622/d528618dnt10q.htm
10-K 10-K 2021-03-26 https://www.sec.gov/Archives/edgar/data/1828326/000119312521096599/d226007d10k.htm
SC 13G 2021-02-16 https://www.sec.gov/Archives/edgar/data/1828326/000110465921024219/tm216584d10_sc13g.htm
8-K 8-K 2021-01-29 https://www.sec.gov/Archives/edgar/data/1828326/000119312521022609/d39828d8k.htm
SC 13D SC 13D 2021-01-27 https://www.sec.gov/Archives/edgar/data/1828326/000119312521019263/d118739dsc13d.htm
3/A OWNERSHIP DOCUMENT 2020-12-17 https://www.sec.gov/Archives/edgar/data/1828326/000110465920136844/xslF345X02/tm2038774-8_3aseq1.xml
3/A OWNERSHIP DOCUMENT 2020-12-17 https://www.sec.gov/Archives/edgar/data/1828326/000110465920136843/xslF345X02/tm2038774-5_3aseq1.xml
3/A OWNERSHIP DOCUMENT 2020-12-17 https://www.sec.gov/Archives/edgar/data/1828326/000110465920136842/xslF345X02/tm2038774-4_3aseq1.xml
3/A OWNERSHIP DOCUMENT 2020-12-17 https://www.sec.gov/Archives/edgar/data/1828326/000110465920136840/xslF345X02/tm2038774-3_3aseq1.xml
3/A OWNERSHIP DOCUMENT 2020-12-17 https://www.sec.gov/Archives/edgar/data/1828326/000110465920136838/xslF345X02/tm2038774-2_3aseq1.xml
3/A OWNERSHIP DOCUMENT 2020-12-17 https://www.sec.gov/Archives/edgar/data/1828326/000110465920136837/xslF345X02/tm2038774-1_3aseq1.xml
8-K FORM 8-K 2020-12-17 https://www.sec.gov/Archives/edgar/data/1828326/000110465920136830/tm2038295d2_8k.htm
8-K FORM 8-K 2020-12-14 https://www.sec.gov/Archives/edgar/data/1828326/000110465920135253/tm2038295d1_8k.htm
4 OWNERSHIP DOCUMENT 2020-12-11 https://www.sec.gov/Archives/edgar/data/1828326/000110465920134761/xslF345X03/tm2037955-9_4seq1.xml
424B4 424B4 2020-12-10 https://www.sec.gov/Archives/edgar/data/1828326/000110465920134286/tm2033264-6_424b4.htm
S-1MEF S-1MEF 2020-12-09 https://www.sec.gov/Archives/edgar/data/1828326/000110465920133354/tm2038064d1_s1mef.htm
EFFECT 2020-12-08 https://www.sec.gov/Archives/edgar/data/1828326/999999999520003445/xslEFFECTX01/primary_doc.xml
3 OWNERSHIP DOCUMENT 2020-12-08 https://www.sec.gov/Archives/edgar/data/1828326/000110465920133279/xslF345X02/tm2037955-8_3seq1.xml
3 OWNERSHIP DOCUMENT 2020-12-08 https://www.sec.gov/Archives/edgar/data/1828326/000110465920133277/xslF345X02/tm2037955-7_3seq1.xml
3 OWNERSHIP DOCUMENT 2020-12-08 https://www.sec.gov/Archives/edgar/data/1828326/000110465920133276/xslF345X02/tm2037955-6_3seq1.xml
3 OWNERSHIP DOCUMENT 2020-12-08 https://www.sec.gov/Archives/edgar/data/1828326/000110465920133275/xslF345X02/tm2037955-5_3seq1.xml
3 OWNERSHIP DOCUMENT 2020-12-08 https://www.sec.gov/Archives/edgar/data/1828326/000110465920133274/xslF345X02/tm2037955-4_3seq1.xml
3 OWNERSHIP DOCUMENT 2020-12-08 https://www.sec.gov/Archives/edgar/data/1828326/000110465920133273/xslF345X02/tm2037955-3_3seq1.xml
3 OWNERSHIP DOCUMENT 2020-12-08 https://www.sec.gov/Archives/edgar/data/1828326/000110465920133271/xslF345X02/tm2037955-2_3seq1.xml
3 OWNERSHIP DOCUMENT 2020-12-08 https://www.sec.gov/Archives/edgar/data/1828326/000110465920133270/xslF345X02/tm2037955-1_3seq1.xml
CERT 2020-12-07 https://www.sec.gov/Archives/edgar/data/1828326/000135445720000756/8A_Cert_FLAC.pdf
8-A12B FORM 8-A12B 2020-12-04 https://www.sec.gov/Archives/edgar/data/1828326/000110465920132424/tm2033264d5_8a12b.htm
CORRESP 2020-12-04 https://www.sec.gov/Archives/edgar/data/1828326/000110465920132422/filename1.htm
CORRESP 2020-12-04 https://www.sec.gov/Archives/edgar/data/1828326/000110465920132420/filename1.htm
CORRESP 2020-11-20 https://www.sec.gov/Archives/edgar/data/1828326/000110465920128043/filename1.htm
S-1 S-1 2020-11-20 https://www.sec.gov/Archives/edgar/data/1828326/000110465920128041/tm2033264-2_s1.htm
DRS 2020-10-15 https://www.sec.gov/Archives/edgar/data/1828326/000110465920115324/filename1.htm